TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Problems

Androgens in postmenopausal women

Key Statistics

  • 5% — Female testosterone vs male levels
  • 300 µg/day — Effective testosterone patch dose
  • 5 mg/day — Typical UK off-label gel dose

Don't-miss facts

  1. Only evidence-based indication for postmenopausal testosterone is HSDD — not mood, energy, cognition, bone or muscle

  2. NICE NG23: consider testosterone if estrogen therapy alone is ineffective for low sexual desire

  3. Diagnose HSDD clinically: distressing symptoms ≥6 months, ≥75% of sexual encounters — testosterone levels do not diagnose it

  4. Check total testosterone before starting and at 2–3 months (BMS 2022); do not measure free testosterone

  5. Prescribe non-oral (transdermal) only; oral testosterone raises LDL and lowers HDL. Usual off-label dose 5 mg/day; effective patch dose 300 µg/day

  6. Apply to clean dry lower abdomen/upper thigh, avoid skin contact with others until dry, wash hands after

  7. Allow ≥8 weeks for response; trial 3 months minimum, stop at 6 months if no improvement; review annually

  8. Avoid: acute liver disease, competitive athletes, upper-normal/high baseline testosterone; do not use DHEA, tibolone or compounded testosterone for HSDD

Evidence at a glance

Proven: transdermal testosterone for HSDD Not proven: cognition, mood, bone, lean mass

Not recommended: oral testosterone, DHEA, tibolone, compounded

Key trial numbers

APHRODITE (n=814, no estrogen): 300 µg/day +2.1 vs +0.7 satisfying episodes/month (p<0.001); 150 µg/day NS ADORE (n=272, natural menopause): +1.69 vs +0.53/month (p=0.0089) Hair growth RR 1.69 (1.33–2.14); acne RR 1.46 (1.11–1.92); no virilisation reported with transdermal APHRODITE endometrial: bleeding 10.6% vs 2.6%, no hyperplasia or carcinoma over 52 weeks

Physiology one-liners

Testosterone ~5% of male levels; 100–400 µg/day, 3–4× estrogen output Premenopause: ovary 25% / adrenal 25% / peripheral 50% → at menopause ovary 50% / adrenal 10% / peripheral 40% Bound 66% SHBG, 33% albumin, 1–2% free; FAI = total testosterone × 100 / SHBG Natural menopause does not sharply drop androgens; BSO drops them 50%

Abbreviation Key

  • HSDD — hypoactive sexual desire disorder/dysfunction
  • DHT — dihydrotestosterone
  • FSD — female sexual dysfunction
  • SHBG — sex hormone binding globulin
  • FSIAD — female sexual interest and arousal disorder
  • FAI — free androgen index
  • DHEA / DHEA-S — dehydroepiandrosterone / its sulfate
  • BMS — British Menopause Society
  • NICE — National Institute for Health and Care Excellence
  • MHRA — Medicines and Healthcare Products Regulatory Agency
  • RCT — randomised controlled trial
  • GMC — General Medical Council
  • BSO — bilateral salpingo-oophorectomy
  • FDA — US Food and Drug Administration
  • POI — premature ovarian insufficiency
  • DSM — Diagnostic and Statistical Manual of Mental Disorders
  • HRT — hormone replacement therapy
  • SWAN — Study of Women’s Health Across the Nation
  • BMD — bone mineral density
  • WHI — Women’s Health Initiative
  • CVD — cardiovascular disease
  • PGWB — Psychological General Wellbeing index
  • HDL / LDL — high-density / low-density lipoprotein

Source: Vigneswaran K, Hamoda H. Androgens in postmenopausal women. The Obstetrician & Gynaecologist 2022;24:228–241. doi:10.1111/tog.12836

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free